Dr John Scott - Mary MacKillop Institute for Health Research (Faculty of Health Sciences)
Accreditation in-progress - Supervisor is eligible to co-supervise with another fully accredited supervisor (Principal Supervisor)
The primary research aim of Dr Scott and his team is to understand the molecular pathways that regulate appetite, mood and behavior in response to hormones and metabolites that signal changes in nutrient availability. His research is specifically focused on the control of the metabolic sensor CaMKK2, which is a major regulator of whole-body energy metabolism and behavior. CaMKK2 dysfunction displays strong links with a range of human diseases including bipolar disorder and schizophrenia, as well as hepatic, prostate and ovarian cancers. A major goal of our research group is to unleash the potential of CaMKK2 as a treatment for psychiatric disorders and cancer, and he has established international collaborations with academic and industrial partners to develop new drugs that target CaMKK2.
Dr Scott graduated with a Bachelor of Science (Hons) from the University of Glasgow and a PhD in Biochemistry from the University of Dundee funded by a prestigious Wellcome Trust Prize scholarship. He moved to Melbourne in 2006 to undertake postdoctoral studies at St Vincents Institute of Medical Research (SVIMR) and established the Neurometabolism group at SVIMR in 2017. Dr Scott is also an Honorary Research Fellow of the Florey Institute of Neuroscience and Mental Health. His group uses a wide range of techniques including biochemistry, cell biology, protein crystallography, mass spectrometry and genetically modified mouse models to decipher the role of the CaMKK2 pathway in the regulation of metabolism and complex behaviour in health and disease.
|:||04 2237 2230 (St Vincent's Institute of Medical Research)|
|:||Staff Directory ProfilePersonal Website|
- A New Therapeutic Target For The Treatment of Castration-Resistant Prostate Cancer (PhD) (Principal Supervisor)
Inhibition of Adenosine Monophosphate???Activated Protein Kinase???3???Hydroxy???3???Methylglutaryl Coenzyme A Reductase Signaling Leads to Hypercholesterolemia and Promotes Hepatic Steatosis and Insulin Resistance, in Hepatology Communications
The autophagy initiator ULK1 sensitizes AMPK to allosteric drugs, in Nature Communications
Ca2+-Calmodulin-dependent Protein Kinase Kinase-2 Is Regulated by Multisite Phosphorylation, in Journal of Biological Chemistry